This content is current only at the time of printing. This document was printed on 21 February 2020. A current copy is located at https://apvma.gov.au/node/29271
You are here
Proposed approval of the new active lokivetmab in the products Cytopoint Solution for Injection for Dogs
This consultation closed on 22 May 2018.
The APVMA is considering an application for approval of the active lokivetmab and registration of the products Cytopoint Solution for Injection for Dogs. The products are to be registered for the treatment of the clinical manifestations of atopic dermatitis in dogs.
We invite comment from 24 April 2018 to 22 May 2018 on whether the application for active approval and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds for registration, including:
- occupational health and safety
- public health
- chemistry and manufacture
- residues in food
- environmental safety
- efficacy and target crop safety.
For more information, see APVMA Gazette notice (page 41) from 24 April 2018.
Please send your written submission by email, post or fax to:
Case Management and Administration Unit
Australian Pesticides and Veterinary Medicines Authority
P O Box 6182
Kingston ACT 2604
Phone: +61 2 6210 4701
Fax: +61 2 6210 4721